Does TOFACITINIB Cause Coronary arterial stent insertion? 34 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 34 reports of Coronary arterial stent insertion have been filed in association with TOFACITINIB (XELJANZ XR). This represents 0.0% of all adverse event reports for TOFACITINIB.
34
Reports of Coronary arterial stent insertion with TOFACITINIB
0.0%
of all TOFACITINIB reports
1
Deaths
13
Hospitalizations
How Dangerous Is Coronary arterial stent insertion From TOFACITINIB?
Of the 34 reports, 1 (2.9%) resulted in death, 13 (38.2%) required hospitalization.
Is Coronary arterial stent insertion Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TOFACITINIB. However, 34 reports have been filed with the FAERS database.
What Other Side Effects Does TOFACITINIB Cause?
Drug ineffective (30,382)
Pain (21,659)
Condition aggravated (16,925)
Arthralgia (15,640)
Fatigue (13,551)
Rheumatoid arthritis (12,277)
Off label use (11,736)
Headache (11,061)
Joint swelling (10,686)
Malaise (9,040)
What Other Drugs Cause Coronary arterial stent insertion?
ROSIGLITAZONE (1,698)
METFORMIN\ROSIGLITAZONE (245)
ADALIMUMAB (175)
EVOLOCUMAB (109)
RANOLAZINE (95)
RISANKIZUMAB-RZAA (94)
AVANDIA (68)
ETANERCEPT (67)
IBRUTINIB (54)
UPADACITINIB (52)
Which TOFACITINIB Alternatives Have Lower Coronary arterial stent insertion Risk?
TOFACITINIB vs TOFERSEN
TOFACITINIB vs TOLNAFTATE
TOFACITINIB vs TOLODODEKIN ALFA
TOFACITINIB vs TOLTERODINE
TOFACITINIB vs TOLVAPTAN